 |
|
Oxycodone for Cancer-Related Pain
Meta-analysis of Randomized Controlled Trials
Colette M. Reid, MB;
Richard M. Martin, BM, PhD;
Jonathan A. C. Sterne, PhD;
Andrew N. Davies, MD;
Geoffrey W. Hanks, DSc
Arch Intern Med. 2006;166:837-843.
To evaluate the efficacy and tolerability of oxycodone in cancer-related pain, we conducted a systematic review of randomized controlled trials. Four studies, comparing oral oxycodone with either oral morphine (n = 3) or oral hydromorphone (n = 1), were suitable for meta-analysis. Standardized mean differences in pain scores comparing oxycodone with control groups were pooled using random-effects models. Overall, there was no evidence that mean pain scores differed between oxycodone and control drugs (pooled standardized mean difference, 0.04; 95% confidence interval [CI], –0.29 to 0.36; P = .8; I2 = 62%). In meta-regression analyses, pain scores were higher for oxycodone compared with morphine (0.20; 95% CI, –0.04 to 0.44) and lower compared with hydromorphone (–0.36; 95% CI, –0.71 to 0.00), although these effect sizes were small. The efficacy and tolerability of oxycodone are similar to morphine, supporting its use as an opioid for cancer-related pain.
Author Affiliations: Departments of Palliative Medicine (Dr Reid and Prof Hanks) and Social Medicine (Drs Martin and Sterne), University of Bristol, Bristol, England; and Department of Palliative Medicine, Royal Marsden Hospital, London, England (Dr Davies).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Other articles noted
Evid. Based Med. 2006;11:159-160.
FULL TEXT
End of contract for Drug and Therapeutics Bulletin: choices.
Baglioni
BMJ 2006;332:1273-1273.
FULL TEXT
|
